SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.37+0.9%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sammaster who wrote (9681)12/7/2003 12:54:47 AM
From: Biomaven  Read Replies (2) of 52153
 
why would US allow norvasc rip-off to be sold in america 3 years before patent expiration

I think this relates to the details of the Waxman-Hatch law that gives drug companies up to a 5-year extension on their patent to compensate for the period it was being developed or under FDA review. The issue here is whether the patent-extension also protects variants of the patented compound - in this case a different salt if I recall correctly. (SEPR for a while talked about this same loophole with respect to a single-isomer version of a drug).

So it's not any policy decision going on here - it's just a possible loophole in the law.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News